**Core tip**: The morphology and quantity of mesenchymal stem cell exosomes (MSCs-exo) are impacted in different inflammatory cytokine environments. Inflammatory cytokines impair the ability of MSCs-exo to promote angiogenesis. For instance, the tumor necrosis factor α and interleukin 6 groups exhibited decreased numbers of angiogenesis-related microRNAs (miRNAs), such as miR-196a-5p, miR-17-5p, miR-146b-5p, miR-21-3p, and miR-320. The same groups also had downregulated angiogenesis-related signaling pathways, such as PI3K-AKT and VEGF. Inflammatory cytokines may lead to changes in exosomal miRNAs that abnormally impact cellular components, molecular function, and biological processes, particularly angiogenesis-related miRNAs.

INTRODUCTION
============

Stem cell transplantation has been developing rapidly and has resulted in breakthroughs for the treatment of various diseases. There is especially an interest in the transplantation of mesenchymal stem cells (MSCs), which are tissue-derived cells with self-renewal abilities. Their exosomes (MSCs-exo) not only contain the unique active components of all stem cells, but also are relatively more safe, are more chemically stable, and have the capacity for targeted delivery to biological pathways of interest\[[@B1]-[@B4]\].

Exosomes were first found *in vitro* in cultured sheep erythrocyte supernatant\[[@B5]\]. They are membranous vesicles with a diameter of 30-150 nm and a density of 1.10-1.18 g/mL. They are able to affect gene regulation by carrying and releasing various bioactive molecules such as microRNAs (miRNAs) and proteins, both of which can then function as paracrine signaling mediators impacting biological pathways relevant to disease processes\[[@B6]\]. MiRNAs are non-coding RNAs 22-25 nucleotides in length\[[@B7]-[@B10]\]. Exosomes are especially important in producing miRNAs that impact angiogenesis\[[@B11]\].

There is promising research on using MSCs-exo to encourage wound healing and to treat inflammatory arthritis and ischemic diseases. However, in treating these diseases, MSCs are exposed to microenvironments filled with numerous inflammatory cytokines, such as vascular cell adhesion molecule-1 (VCAM-1), tumor necrosis factor (TNF) α, and interleukin (IL) 6. The effects of these inflammatory cytokines on the morphology and quantity of MSCs-exo and how these effects impact the production of miRNAs and downstream regulatory mechanisms are largely unknown. In this study, we analyzed the effects of VCAM-1, TNFα, and IL6 on the morphology and quantity of MSCs-exo, how these effects enhance differential expression of miRNAs, and how the target genes of these miRNAs and their associated regulatory mechanisms are regulated.

MATERIALS AND METHODS
=====================

Cell culture
------------

Human umbilical mesenchymal stem cells were obtained from the Polywin Corporation (Guangzhou, China). The phenotypes of the MSCs were characterized by flow cytometric analysis of cell surface antigens, including tests for the cluster of differentiation (CD)29, CD34, CD44, CD73, and CD105. The MSCs were divided into four groups: Control group: MSCs (1.0 × 10^5^ cells/mL) were cultured in a serum-free DMEM/F12 (Sigma-Aldrich, United States) medium for 48 h; VCAM-1 group: MSCs (1.0 × 10^5^ cells/mL) were cultured in a serum-free DMEM/F12 (Sigma-Aldrich) medium, and VCAM-1 reagent (ADP5, R&D Systems, United States) was added to the medium at a concentration of 20 ng/mL for 48 h; TNFα group: MSCs (1.0 × 10^5^ cells/mL) were cultured in a serum-free DMEM/F12 (Sigma-Aldrich) medium, and TNFα reagent (T6674, Sigma-Aldrich) was added to the medium at a concentration of 20 ng/mL for 48 h; and IL6 group: MSCs (1.0 × 10^5^ cells/mL) were cultured in a serum-free DMEM/F12 (Sigma-Aldrich) medium, and IL6 reagent (200-06-20, PeproTech, United States) was added to the medium at a concentration 20 ng/mL for 48 h. The number, distribution, and morphology of cells in each group were observed under a microscope at 100× or 200× magnification for 48 h.

Exosome isolation
-----------------

Exosomes were isolated from the culture supernatant by ultracentrifugation according to methods described previously\[[@B12],[@B13]\]. Briefly, the culture medium of each group was collected and centrifuged at 2000 *× g* for 10 min at 4 °C. The supernatant was then centrifuged at 10000 *× g* for 10 min at 4 °C. Next, the supernatant was passed through a 0.2-μm filter (Steradisc; Kurabo, Bio-Medical Department, Tokyo, Japan). The filtrate was ultracentrifuged at 100000 × *g* for 70 min at 4 °C (Type 70Ti ultracentrifuge; Beckman Coulter, Inc., Brea, CA, United States). The precipitate was next rinsed with phosphate buffered saline (PBS) and ultracentrifuged at 100000 × *g* for 70 min at 4 °C. The exosome-enriched fraction was next reconstituted in PBS for further studies.

Characteristics and distributions of exosomes in each group were observed. The particle size and concentration of exosomes in each group were measured by nanoparticle tracking analysis.

Differential miRNA analysis and target gene and regulatory signal pathway prediction
------------------------------------------------------------------------------------

The miRNAs of MSCs-exo were sequenced by BGISEQ-500 technology in each group. Sequenced data were compared with miRBase and other non-coding databases. Bioinformatics analysis pipeline steps for miRNA sequencing were: (1) Filtering small RNAs: 18-30 nt RNA segments were separated by polyacrylamide gel electrophoresis (PAGE); (2) 3' adaptor ligation: A 5-adenylated, 3-blocked single-stranded DNA adapter was linked to the 3' end of selected small RNAs from step 1; (3) Reverse primer annealing: the RT primer was added to the solution from step 2 and cross-linked to the 3' adapter of the RNAs and to excess free 3' adapter; (4) 5' adaptor ligation: a 5' adaptor was linked to the 5\' end of the product from step 3. The adaptor was attached to the end only, not to the 3' adaptor or RT primer hybrid chain, thus greatly reducing self-ligation; (5) cDNA synthesis: The RT primers in step 3 were reverse extended to synthesize cDNA strands; (6) PCR amplification: High-fidelity polymerase was used to amplify cDNA, and cDNA with both 3' and 5' adaptors was enriched; (7) Library fragment selection: The PCR products of 100-120 bp were separated by PAGE to eliminate primer dimers and other byproducts; (8) Library quantitative and pooling cyclization; (9) Eliminating the low-quality reads, adaptors and other contaminants to obtain clean reads; (10) Summarizing the length distribution of the clean tags, common, and specific sequences between samples; (11) Assigning the clean tags to different categories; (12) Predicting novel miRNAs; (13) Function annotation of known miRNAs; and (14) Comparing clean reads to the reference base group and other small RNA databases using AASRA software \[[@B14]\], except that Rfam was compared with cmsearch\[[@B15]\]. We used TPM\[[@B16]\] to standardize miRNA expression levels and predicted target genes using RNAhybrid\[[@B17]\], miRanda\[[@B18]\], and TargetScan\[[@B19]\].

Hierarchical clustering analysis showed differentially expressed miRNAs by functional pheatmap. The *P*-values obtained from the differential gene expression tests were corrected by controlling the false discovery rate (FDR)\[[@B20]\] as more stringent criteria with smaller FDRs and bigger fold-change values can be used to identify differentially expressed miRNAs.

Gene ontology (GO) enrichment analysis was performed to identify all GO terms that are significantly enriched in a list of target genes of differentially expressed miRNAs, as well as the genes that correspond to specific biological functions.

The hypergeometric test was then used to find significantly enriched GO terms based on this database (<http://www.geneontology.org/>). Pathway-based analyses were used to discover the biological functions of target genes using KEGG\[[@B21]\] (the major public pathway-related database).

In vitro Matrigel tube formation assay
--------------------------------------

HUVECs (4.0 × 10^4^, serum-starved overnight) were seeded in a 96-well plate, cultured in 5% CO~2~ overnight, and then treated with PBS (control), control scrambled MSCs-exo, MSCs-exo^TNFα^ (5 × 10^9^, stimulated with TNFα), or MSCs-exo^IL6^ (5 × 10^9^, stimulated with IL6). The plates were previously coated with 150 μL of growth factor-reduced Matrigel (356234, Corning, United States) in serum-free medium. Tube formation ability of control or MSCs-exo-treated HUVECs was examined by determining the total number of tubes formed and branching points in 4 to 6 h. Each condition in each experiment was assessed at least in duplicate.

Western blot analysis
---------------------

HUVECs (4.0 × 10^4^) were treated with PBS (control), control scrambled MSCs-exo, MSCs-exo^TNFα^ (5 × 10^9^, stimulated with TNFα), or MSCs-exo^IL6^ (5 × 10^9^, stimulated with IL6). The effect of MSCs-exo treatment on PI3K-AKT and MAPK, which are related to angiogenic signaling, was examined by measuring the expression of AKT (1:1000 dilution, 4691S, Cell Signaling Technology, Danvers, MA, United States), phospho-AKT (1:1000 dilution, 13038S, Cell Signaling Technology), phospho-p44/42 MAPK (Erk1/2) (1:2000 dilution, 4370S, Cell Signaling Technology), and p44/42 MAPK (Erk1/2) (1:1000 dilution, 4695S, Cell Signaling Technology) in endothelial cells by Western blot. Each condition in each experiment was assessed at least in triplicate.

Statistical analysis
--------------------

The data from each group were collected and analyzed using SPSS 11.5 software (IBM SPSS China, Shanghai, china). Numerical data are presented as the mean ± SE; comparisons between groups were evaluated by Student's *t*-test or ANOVA, with *P* \< 0.05 considered significant.

RESULTS
=======

Phenotypic characterization of MSCs
-----------------------------------

Cell purity (85% to 95%) was determined *via* flow cytometry. The cells were positive for mesenchymal cell markers such as CD29, CD44, CD73, and CD105 and negative for hematopoietic cell markers such as CD34 and HLA-DR (Figure [1](#F1){ref-type="fig"}).

![Flow cytometric analysis of mesenchymal stem cell-related cell surface markers. High expression of positive mesenchymal cell markers (CD29, CD44, CD73, and CD105), and low expression of negative cell markers such as CD34 and HLA-DR were observed. *n* = 3 to 5; *P* \< 0.05,](WJSC-11-859-g001){#F1}

Effect of inflammatory cytokines on MSCs-exo
--------------------------------------------

The VCAM-1 group had small regularly shaped MSCs-exo. The TNFα group had large irregularly shaped MSCs-exo. The IL6 group had medium regularly shaped MSCs-exo (Figure [2](#F2){ref-type="fig"})

![Morphology of mesenchymal stem cell exosomes (magnification, ×65000). A-D: Mesenchymal stem cell exosomes (MSCs-exo) in (A) the control group (yellow arrow), (B) the vascular cell adhesion molecule-1 group (yellow arrow), (C) the tumor necrosis factor α group (yellow arrow), and (D) the interleukin 6 group (yellow arrow).](WJSC-11-859-g002){#F2}

The density of MSCs-exo was 7.42 × 10^8^/mL in the control group, 1.10 × 10^9^/mL in the VCAM-1 group, 7.37 × 10^8^/mL in the TNFα group, and 3.01 × 10^8^/mL in the IL6 group (Figure [3](#F3){ref-type="fig"}).

![Nanoparticle tracking analysis. A-D: Density of exosomes of different sizes in (A) the control group, (B) the vascular cell adhesion molecule-1 group, (C) the tumor necrosis factor α group, and (D) the interleukin 6 group.](WJSC-11-859-g003){#F3}

Effect of differential miRNA expression, secondary to inflammatory cytokine exposure, on biological function
------------------------------------------------------------------------------------------------------------

Correlation analyses showed that the miRNA expression profiles in the IL6 group (0.583) and TNFα group (0.697) were more different from that of the control group than that in the VCAM1 group (0.985) (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). The top 10 miRNAs in each group are shown in Table [1](#T1){ref-type="table"}. Many miRNAs, particularly some important angiogenesis-related miRNAs, were downregulated in the TNFα group and IL6 group compared to the control group (Tables [2](#T2){ref-type="table"}-[4](#T4){ref-type="table"} and Figure [6](#F6){ref-type="fig"}). Hierarchical clustering indicated that the expression levels of the majority of miRNAs in the IL6 group were downregulated compared with those of the control group (Figure [7](#F7){ref-type="fig"}). According to GO enrichment analysis, miRNAs in exosomes exposed to inflammatory cytokines, compared to controls, had a different regulatory effect on cellular components, molecular function, and biological processes (Figure [8](#F8){ref-type="fig"}). More specifically, pathway enrichment analysis showed that the target genes of the differentially expressed miRNAs, including those related to angiogenesis, differed among the four groups (Figures [9](#F9){ref-type="fig"} and [10](#F10){ref-type="fig"}). The following angiogenesis-related pathways were more down-regulated in the TNFα and IL6 groups than in the control group: The PI3K-AKT signaling pathway (*Q* = 0.0978197212 and 0.0581120875 in the TNFα group and IL6 group, respectively), the MAPK signaling pathway (*Q* = 0.5775485 and 0.9837761532 in the TNFα group and IL6 group, respectively), and the VEGF signaling pathway (Q = 0.4082212190 and 0.1711566 in the TNFα group and IL6 group, respectively) (Figures [10](#F10){ref-type="fig"}-[13](#F13){ref-type="fig"}).

###### 

Differentially expressed miRNAs

  **Top 10 differentially expressed miRNAs**                                                                                                                                                  
  -------------------------------------------- --------- ---------- -------------------------- --------- ---------- -------------------------- --------- ---------- ------------------------- ---------
  miR-21-5p                                    1544110   76933.99   miR-21-5p                  1640334   70885.38   miR-21-5p                  1454726   70066.87   miR-21-5p                 1323387
  miR-127-3p                                   159283    9724.54    miR-127-3p                 259830    11250.19   miR-100-5p                 408192    19681.79   miR-199a-3p,miR-199b-3p   317377
  miR-199a-3p,miR-199b-3p                      139220    8499.65    miR-199a-3p, miR-199b-3p   155376    6727.51    miR-127-3p                 321306    15492.41   miR-127-3p                300549
  miR-100-5p                                   132865    8111.67    miR-100-5p                 140774    6095.27    miR-199a-3p, miR-199b-3p   271902    13110.3    miR-100-5p                265054
  miR-222-3p                                   89564     5468.06    miR-26a-5p                 107800    4667.55    miR-23a-3p                 140623    6780.42    miR-34a-5p                178542
  miR-26a-5p                                   77524     4732.99    miR-34a-5p                 86786     3757.68    miR-222-3p                 129932    6264.93    miR-23a-3p                144385
  miR-34a-5p                                   76681     4681.52    miR-451a                   77297     3346.83    miR-146a-5p                128078    6175.54    miR-222-3p                111957
  miR-181a-5p                                  67287     4108       miR-23a-3p                 71930     3114.44    miR-34a-5p                 119952    5783.73    miR-146a-5p               100038
  miR-411-5p                                   56606     3455.91    miR-196a-5p                63939     2768.45    miR-143-3p                 101398    4889.11    miR-26a-5p                98114
  miR-143-3p                                   49739     3036.66    miR-181a-5p                62752     2717.05    miR-26a-5p                 99628     4803.76    miR-181a-5p               97685

Count is the number of mapped tags, and the value in parentheses is the total number. Transcripts per kilobase million is the standardized expression value. VCAM-1: Vascular cell adhesion molecule-1; TNF: Tumor necrosis factor; IL6: Interleukin 6; TPM: Transcripts per kilobase million.

###### 

Top 10 differentially expressed miRNAs in each group (Poisson distribution screening)

  **Comparison of top 10 differentially expressed miRNAs**                                                                                                                                                                                                                                        
  ---------------------------------------------------------- ------- ------- --------- --------- ---------- ------ ----------- ----------- ------------- -------- -------- --------- ---------- ---------- ------ --- --- ------------- ------- ------- --------- --------- ---------- ------ --- ---
  miR-146a-5p                                                20510   5173    1252.18   223.98    -2.483     Down   0           0           miR-146a-5p   20510    128078   1252.18   6175.54    2.302123   Up     0   0   miR-3529-3p   473     8930    28.88     278.05    3.267202   Up     0   0
  miR-149-5p                                                 4558    2391    278.27    103.53    -1.42644   Down   0           0           miR-342-3p    2117     7130     129.25    343.79     1.411363   Up     0   0   miR-320c      1276    7983    77.9      248.57    1.673957   Up     0   0
  miR-222-3p                                                 89564   48444   5468.06   2097.54   -1.38233   Down   0           0           miR-23a-3p    42777    140623   2611.62   6780.42    1.37643    Up     0   0   miR-24-3p     11151   50968   680.79    1586.99   1.221011   Up     0   0
  miR-29a-3p                                                 8451    5054    515.95    218.83    -1.23742   Down   0           0           miR-100-5p    132865   408192   8111.67   19681.79   1.278791   Up     0   0   miR-7-5p      16653   101     1016.7    3.14      -8.33891   Down   0   0
  miR-451a                                                   2760    77297   168.5     3346.83   4.311975   Up     0           0           miR-337-3p    5655     16027    345.25    772.77     1.162398   Up     0   0   miR-196a-5p   26485   11440   1616.96   356.21    -2.18248   Down   0   0
  miR-490-5p                                                 1839    475     112.27    20.57     -2.44836   Down   2.00E-305   1.20E-303   miR-409-3p    4207     11169    256.85    538.54     1.068127   Up     0   0   miR-451a      2760    1658    168.5     51.62     -1.70675   Down   0   0
  miR-1246                                                   1812    6191    110.63    268.06    1.276813   Up     1.39E-276   8.02E-275   miR-221-3p    4067     10541    248.3     508.26     1.033482   Up     0   0   miR-379-5p    13430   8083    819.93    251.68    -1.70391   Down   0   0
  miR-181a-2-3p                                              3400    2008    207.58    86.94     -1.25558   Down   2.31E-219   1.18E-217   miR-7-5p      16653    136      1016.7    6.56       -7.27598   Down   0   0   miR-196b-5p   18735   15676   1143.81   488.1     -1.2286    Down   0   0
  miR-204-5p                                                 3116    1757    190.24    76.08     -1.32223   Down   3.36E-218   1.66E-216   miR-196a-5p   26485    8359     1616.96   403.05     -2.00425   Down   0   0   miR-424-5p    12774   11917   779.88    371.06    -1.0716    Down   0   0
  miR-378e                                                   2       817     0.12      35.37     8.203348   Up     4.36E-186   2.00E-184   miR-26b-5p    6496     3410     396.59    164.42     -1.27026   Down   0   0   miR-26b-5p    6496    6086    396.59    189.5     -1.06545   Down   0   0

*P*-values were corrected. TPM: Transcripts per kilobase million; FDR: False discovery rate; VCAM-1: Vascular cell adhesion molecule-1; TNF: Tumor necrosis factor; IL6: Interleukin 6.

###### 

Comparison of differentially expressed angiogenesis-related miRNAs between the TNFα group and control group

  **miRNA id**      **Count (control)**   **Count** **(TNFα)**   **TPM (control)**   **TPM (TNFα)**   **Log2 ratio (TNFα/ control)**   **Up/ down-regulation (TNFα/ control)**   ***P***    **FDR**
  ----------------- --------------------- ---------------------- ------------------- ---------------- -------------------------------- ----------------------------------------- ---------- ----------
  hsa-miR-196a-5p   26485                 8359                   1616.96             403.05           -2.004253263                     Down                                      0          0
  hsa-miR-320e      161                   46                     9.83                2.22             -2.14663174                      Down                                      5.95E-23   6.85E-22

*P*-values were corrected. TPM: Transcripts per kilobase million; FDR: False discovery rate; TNF: Tumor necrosis factor.

###### 

Comparison of differentially expressed angiogenesis-related miRNAs between the IL6 group and control group

  **miRNA id**      **Count (control)**   **Count (IL6)**   **TPM (control)**   **TPM (IL6)**   **Log2 ratio (IL6/control)**   **Up/down-regulation (IL6/control)**   ***P***    **FDR**
  ----------------- --------------------- ----------------- ------------------- --------------- ------------------------------ -------------------------------------- ---------- ----------
  hsa-miR-196a-5p   26485                 11440             1616.96             356.21          -2.182484067                   Down                                   0          0
  hsa-miR-17-5p     252                   138               15.39               4.3             -1.839584667                   Down                                   2.24E-35   2.98E-34
  hsa-miR-146b-5p   78                    44                4.76                1.37            -1.79678568                    Down                                   1.08E-11   7.53E-11
  hsa-miR-21-3p     440                   358               26.86               11.15           -1.268415595                   Down                                   4.66E-35   6.02E-34
  hsa-miR-320e      161                   153               9.83                4.76            -1.046229843                   Down                                   1.78E-10   1.11E-09

*P*-values were corrected. TPM: Transcripts per kilobase million; FDR: False discovery rate; IL6: Interleukin 6.

![Correlation analyses between groups. Blue color represents the correlation coefficient (the deeper the blue, the stronger the correlation). VCAM-1: Vascular cell adhesion molecule-1; TNF: Tumor necrosis factor; IL6: Interleukin 6.](WJSC-11-859-g004){#F4}

![Distribution of differentially expressed miRNAs in different groups. VCAM-1: Vascular cell adhesion molecule-1; TNF: Tumor necrosis factor; IL6: Interleukin 6.](WJSC-11-859-g005){#F5}

![Volcano plots. A-C: Volcano plots of (A) vascular cell adhesion molecule-1 group *vs* control group, (B) tumor necrosis factor α group *vs* control group, and (C) interleukin 6 group *vs* control group. The X axis is the log2(Fold change), and the Y axis is the -log10(FDR), with green points indicating down-regulation \[log2(Fold old change) ≤ -1 and FDR ≤ 0.001\] and red points indicating upregulation \[log2(Fold change) ≥ 1 and FDR ≤ 0.001\]. FDR: False discovery rate.](WJSC-11-859-g006){#F6}

![Hierarchical clustering of differentially expressed miRNAs. A: Vascular cell adhesion molecule-1 group *vs* control group; B: Tumor necrosis factor α group *vs* control group; C: Interleukin 6 group *vs* control group. The X axis represents each pair of differences, and the Y axis represents differentially expressed miRNAs. The colors indicate the fold change, with red showing up-regulation, and blue showing down-regulation. TNF: Tumor necrosis factor; IL6: Interleukin 6.](WJSC-11-859-g007){#F7}

![Gene ontology enrichment analysis of gene targets of differentially expressed miRNAs. A: Vascular cell adhesion molecule-1 group *vs* control group; B: Tumor necrosis factor α group *vs* control group; C: Interleukin 6 group *vs* control group. The X axis shows the number of differently expressed genes (their square root value), and the Y axis shows GO terms. All GO terms are grouped into three ontologies: Blue indicates biological process, brown indicates cellular components, and red indicates molecular function](WJSC-11-859-g008){#F8}

![Pathway enrichment analysis of gene targets of differentially expressed miRNAs. A: Comparison of the top 20 enriched pathway terms between vascular cell adhesion molecule-1 (VCAM-1) group and control group; B: Comparison of the Kyoto Encyclopedia of Genes and Genomes (KEGG) classification between VCAM-1 group and control group; C: Comparison of the top 20 enriched pathway terms between tumor necrosis factor (TNF) α group and control group; D: Comparison of the KEGG classification between TNFα group and control group; E: Comparison of the top 20 enriched pathway terms between interleukin 6 (IL6) group and control group; F: Comparison of the KEGG classification between IL6 group and control group. A, C, and E: The top 20 enriched pathway terms displayed as scatterplots. The rich factor is the ratio of target gene numbers annotated in this pathway term to all gene numbers annotated in this pathway term. The greater the rich factor, the greater the degree of enrichment. The Q-value is the corrected *P*-value and ranges from 0-1; the lower the Q-value, the greater the level of enrichment; B, D, and F: The X axis shows the number of target genes, and the Y axis shows the second KEGG pathway terms. The first pathway terms are indicated using different colors. The second pathway terms are subgroups of the first pathway terms and are grouped together on the X axis on the right side.](WJSC-11-859-g009){#F9}

![Gene ontology enrichment analysis of angiogenesis-related genes. A: The number of angiogenesis-related genes in the vascular cell adhesion molecule-1 (VCAM-1) group; B: The proportion of angiogenesis-related genes in the VCAM-1 group; C: The number of angiogenesis-related genes in the tumor necrosis factor (TNF) α group; D: The proportion of angiogenesis-related genes in the TNFα group; E: The number of angiogenesis gene distributions in the interleukin 6 (IL6) group; F: The proportion of angiogenesis-related genes in the IL6 group; G: Comparison of the number of angiogenesis-related genes in the three groups to that of the control group.](WJSC-11-859-g010){#F10}

![Regulatory mechanism of the PI3K-AKT signal pathway in different groups. A: Vascular cell adhesion molecule-1 group; B: Tumor necrosis factor α group; C: Interleukin 6 group. Up-regulated genes are marked with red borders and down-regulated genes with green borders. Unchanged genes are marked with black borders.](WJSC-11-859-g011){#F11}

![Regulatory mechanism of the MAPK signal pathway in different groups. A: Vascular cell adhesion molecule-1 group; B: Tumor necrosis factor α group; C: Interleukin 6 group. Up-regulated genes are marked with red borders and down-regulated genes with green borders. Unchanged genes are marked with black borders.](WJSC-11-859-g012){#F12}

![Regulatory mechanism of the VEGF signal pathway in different groups. A: Vascular cell adhesion molecule-1 group; B: Tumor necrosis factor α group; C: Interleukin 6 group. Up-regulated genes are marked with red borders and down-regulated genes with green borders. Unchanged genes are marked with black borders.](WJSC-11-859-g013){#F13}

MSCs-exo promote endothelial cell angiogenesis
----------------------------------------------

The ability of MSCs-exo to enhance tube formation was assessed using a Matrigel assay. MSCs-exo, on average, caused an increase in tube formation and branching (*P* \< 0.05; Figure [14](#F14){ref-type="fig"}) compared to the untreated control group. The angiogenesis effect of MSCs-exo stimulated with TNFα and IL6 was lower than that cultured without TNFα or IL6. This finding confirmed that MSCs-exo can promote angiogenesis (Figure [14](#F14){ref-type="fig"}).

![Tube formation in endothelial cells treated with mesenchymal stem cell exosomes. A: Micrograph showing human umbilical vein endothelial cells (HUVECs) cultured on Matrigel-coated plates in medium with phosphate buffered saline (control); B: Micrograph showing HUVECs cultured on Matrigel-coated plates in medium with mesenchymal stem cell exosomes (MSC-exo); C: Micrograph showing HUVECs cultured on Matrigel-coated plates in medium with MSCs-exo stimulated with tumor necrosis factor α; D: Micrograph showing HUVECs cultured on Matrigel-coated plates in medium with MSCs-exo stimulated with interleukin 6; E: The number of tubes formed in each group; F: The number of branching points in each group.](WJSC-11-859-g014){#F14}

MSCs-exo stimulated with IL6 inhibit PI3K-AKT signaling pathway activation in endothelial cells
-----------------------------------------------------------------------------------------------

We observed a decline in the expression of phosphorylated AKT (pAKT) in endothelial cells after MSCs-exo were stimulated with IL6, although MSC-EV treatment had no effect on the expression of their unphosphorylated forms (Figure [15](#F15){ref-type="fig"}).

![Western blot analysis. Western blot was performed to detect the expression of the indicated proteins in endothelial cells treated with phosphate buffered saline (control), mesenchymal stem cell exosomes (MSCs-exo), MSCs-exo^TNFα^ (stimulated with tumor necrosis factor α), MSCs-exo^IL6^ (stimulated with interleukin 6). GAPDH was used as an internal loading control. TNF: Tumor necrosis factor; IL6: Interleukin 6.](WJSC-11-859-g015){#F15}

DISCUSSION
==========

MSCs have been used to treat cardiovascular diseases (CVDs) and represent a promising cell-based therapy for regenerative medicine and the treatment of inflammatory and autoimmune diseases\[[@B22]\]. Their treatment efficacy hinges on their ability to alter disease-specific pathways *via* secreted miRNAs, so it is imperative to understand how disease environments, which often are inflammatory, can impact secreted miRNAs and thus potentially their treatment efficacy. MSCs-exosomes are used for treating CVDs such as acute myocardial infarction, stroke, pulmonary hypertension, and septic cardiomyopathy\[[@B23]\]. Biological properties of MSCs-exo have rendered them as a new strategy for wound regeneration and ischemic disease\[[@B24]-[@B26]\]. MSCs-exo exert an anti-inflammatory effect on T and B lymphocytes independently of MSCs priming. The potential therapeutic effects also were demonstrated in inflammatory arthritis\[[@B27]\].

Ischemic diseases, trauma, and immunological diseases are all accompanied by inflammatory reactions, and a large number of inflammatory cytokines including VCAM-1, TNFα, and IL6 are involved in the progression of these diseases. T cells are activated dependent on VCAM-1 interactions\[[@B28]\]. VCAM-1 plays a "backup" role in hASC contact-dependent immune suppression\[[@B29]\]. TNFα is a multifunctional cytokine that acts as a central biological mediator for critical immune functions, including inflammation, infection, and antitumor responses\[[@B30]\]. IL6 plays an important role in the inflammatory response following hypoxic-ischemic encephalopathy\[[@B31]\]. Therefore, the biological properties of MSCs-exos and their therapeutic effects need to be studied together with the inflammatory factors. A large amount of evidence suggests that the effect of MSCs-exo therapeutics will be affected by the inflammatory environment with regard to most of CVDs and ischemic diseases\[[@B32]-[@B40]\].

Some previous reports showed\[[@B41]\] the effect of stimulation with cytokines interferon γ and TNFα on adipose MSCs (AMSCs). Pro-inflammatory stimuli could enhance the immunosuppressive functions of AMSC-derived exosomes. There was an increase in the expression of miRNAs (miR-34a-5p, miR21, and miR146a-5p) in exosomes produced by pre-activated AMSCs compared to those released by untreated cells.

The present study also found that the inflammatory cytokines VCAM-1, TNFα, and IL6 impact the size and morphology of MSCs-exo as well as the diversity of miRNAs they can produce, especially miRNAs impacting angiogenesis. According to GO enrichment analysis, miRNAs in exosomes exposed to inflammatory cytokines, compared to controls, had a different regulatory effect on cellular proliferation and differentiation, molecular signal transduction, immunosuppressive functions, angiogenesis and so on.

Some observed effects suggested that inflammatory cytokines impaired the ability of MSCs-exo to promote angiogenesis. For example, the TNFα and IL6 groups exhibited decreased numbers of angiogenesis-related miRNAs, such as miR-196a-5p, miR-17-5p, miR-146b-5p, miR-21-3p, and miR-320. The same groups also had downregulated angiogenesis-related signaling pathways, such as PI3K-AKT, MAPK, and VEGF. However, other effects suggested that inflammatory cytokines may promote the ability of MSCs-exo to encourage angiogenesis. Exosomes contained hsa-mir-4488, hsa-mir-671-5p, and hsa-mir-4446-3p after VCAM-1 stimulation, hsa-mir-4488, hsa-mir-671-5p, and hsa-miR-497-5p after TNFα stimulation, and hsa-mir-4488, hsa-miR-145-5p, and hsa-miR-1260a after IL6 stimulation, all of which promote angiogenesis. More specifically, hsa-miR-671-5p encourages NM_006500.2 to produce the downstream product VEGFb, which activates the VEGF pathway and thereby promotes angiogenesis. Hsa-miR-671-5p also encourages NM_001773.2 to produce CD34, which in turn activates the PI3K-AKT pathway, this promoting cell proliferation and angiogenesis. It is unclear what the ultimate results of these competing effects on angiogenesis would be.

Our study demonstrated that MSCs-exo perhaps induced HUVECs to form capillary-like structures *in vitro*. The effect of MSCs-exo in promoting angiogenesis would be reduced when the stem cells were subjected to TNFα and IL6 stimulation. Besides endothelial cell angiogenesis-related molecular expression, functional characteristics such as the PI3K-AKT signaling pathway may be down-regulated in MSCs-exo that were stimulated with IL6.

The major limitation of this study is that it was conducted *in vitro*. Further research needs to be conducted *in vivo* using an animal model that more closely mirrors the inflammatory environment to which MSCs are exposed when administered for treatment in humans.

In conclusion, inflammatory cytokines may lead to changes in exosomal miRNAs that abnormally impact cellular components, molecular function, and biological processes. Further *in vivo* research needs to be conducted to explore how the treatment efficacy of MSCs is impacted by these inflammatory-induced changes in exosomes and their miRNAs.
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Research background
-------------------

Stem cell transplantation has been developing rapidly and has resulted in breakthroughs for the treatment of various diseases.

Research motivation
-------------------

Treatments utilizing stems cells often require stem cells to be exposed to inflammatory environments, such as vascular cell adhesion molecule-1, tumor necrosis factor α (TNFα), and interleukin 6 (IL6). Stem cell-derived exosomes are especially important in producing miRNAs that impact angiogenesis.

Research objectives
-------------------

MicroRNAs (miRNAs) are RNAs 0-20 nucleotides in length, which are derived from hairpin-like precursor miRNAs. They acts as important regulators of mRNA expression. It has been reported that miRNAs play critical roles in some cells and have the potential as diagnostic and therapeutic biomarkers.

Research methods
----------------

The morphology and quantity of mesenchymal stem cell (MSC) exosomes (MSCs-exo) are influenced by different inflammatory cytokine environments.

Research results
----------------

The morphology and quantity of each group of MSC exosomes were observed and measured. The miRNAs in MSCs-exo were sequenced. Differential expression of miRNAs and their target genes as well as the related regulatory mechanisms were researched.

Research conclusions
--------------------

TNFα and IL6 may influence the expression of miRNAs that down-regulate the PI3K-AKT, MAPK, and VEGF signaling pathways; particularly, IL6 significantly down-regulates the PI3K-AKT signaling pathway.

Research perspectives
---------------------

Overall, inflammatory cytokines may lead to changes in exosomal miRNAs that abnormally impact cellular components, molecular function, and biological process, particularly angiogenesis.
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